Trends & Analysis

2026 ideas
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Machine learning

2026: What will change in preclinical and clinical development?

How will preclinical discovery and clinical trials change in the coming year? And what role will regulators play? Diana Turner asks industry leaders for their predictions for 2026. A number of innovations are predicted to influence R&D in 2026, in both preclinical and clinical trials, including… Read More

#Exclusive Content #Trends & Analysis

2026 ideas
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Machine learning

Drug discovery and development in 2026

Which drug modalities will dominate the market, and which global regions will be most influential? Diana Turner asks industry leaders for their predictions for 2026. The opportunities and challenges facing biotech and biopharma in 2026 are concisely summarised by Dr Kevin Land, Executive Medical Director Biotherapies… Read More

#Exclusive Content #Trends & Analysis

2026 ideas
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #Gene editing

CGT in 2026: In vivo, greater specificity and next-gen platforms

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. Read More

#Exclusive Content #Trends & Analysis

2026 ideas
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Machine learning

2026: An AI tipping point for drug discovery

How big a role will AI play in the coming year? Diana Turner asks industry leaders for their predictions. As with all sectors, the role of artificial intelligence (AI) in drug discovery is expected to significantly increase in 2026 and beyond. Richard Young, CSO… Read More

#Exclusive Content #Trends & Analysis

Tower Bridge, London
#Drug discovery #Events #Investment #London Life Sciences Week #Market reporting

‘Good vibrations’ at London Life Science Week bode well for 2026

Jefferies’ Global Healthcare Conference held every November and coinciding with London Life Science Week (LLSW), is staking its claim as one of the world’s ‘must attend’ biotech investor events – and a vital barometer going into the New Year. DDW found the atmosphere refreshingly upbeat.  “Going into… Read More

#Exclusive Content #Trends & Analysis

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top biopharma companies report 4% market growth in Q3 2025

The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.   This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on… Read More

#Business & Investment #News #Trends & Analysis

European biotech
#Biologics / Biotechnology #Biotech #Europe #European Commission #European Union

Is the European Biotech Act a one-shot solution for the biotech sector?

For European Biotech Week, Diana Turner and Dr Claire Skentelbery, Director General, EuropaBio, examine the potential impact of the European Biotech Act. The European Biotech Act was first introduced by Ursula von der Leyen in 2024 in her paper ‘Europe’s Choice: Political Guidelines For The Next… Read More

#Exclusive Content #Trends & Analysis

#Diabetes #GLP-1 #Mass spectrometry / NMR #Weight loss

How mass spectrometry is supporting GLP-1 breakthroughs in diabetes care

Kean Woodmansey, Senior Global Market Development Manager, Discovery (DMPK), SCIEX, examines how molecular precision is being enabled in GLP-1 therapies through the use of mass spectrometry. On Diabetes Alert Day in March, professionals across healthcare, research, and pharmaceutical development reflected on the pressing need for improved diabetes detection and treatment. Read More

#Exclusive Content #Trends & Analysis

European Commission President Ursula von der Leyen
#Biotech #Biotech hubs #Europe #European Commission #European Union #Market reporting

Can Europe take the lead on biotech?

With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech? Diana Turner reports.  While biotech has so far been dominated by the US, since the inauguration of Donald Trump in January 2025, there has been considerable uncertainty, with significant… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Artificial intelligence (AI) #Cancer research #Data management #Diversity #Oncology #Quantum computing

Opportunities and challenges in oncology

DDW Editor Reece Armstrong takes a look at some of the recent activity in cancer research and examines where the biggest opportunities are in oncology.  In January this year, researchers from the University of Toronto (UoT) and Insilico Medicine published a paper detailing how quantum computing combined with generative… Read More

#Cancer Research #Exclusive Content #Trends & Analysis

Quantum computing concept
#AI / data analytics / healthtech / informatics #Clinical trials #Computer modelling #Quantum computing

How quantum computing is revolutionising drug development

Saurabh Singal, Founder of Molecule AI, examines the impact that quantum computing can, and will have, on drug discovery and development. A quantum leap in pharma In 2019, Google announced that its quantum computer had achieved a groundbreaking milestone1 – solving a problem in 200 seconds that would take the… Read More

#Exclusive Content #Trends & Analysis

#2025 predictions #Drug development #Drug discovery #Regulatory

New modalities: Industry predictions for 2025

DDW’s Megan Thomas spoke with industry experts about their predictions for drug discovery opportunities in 2025. Previously, with a focus on technology, machine learning (ML) and artificial intelligence (AI), as well as neuroscience, cancer research, cell and gene therapy, diagnostics and regulation and drug policy. This is the final… Read More

#Exclusive Content #Regulatory #Trends & Analysis